AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 51 min read$CVKD

Pham Quang X sold $36K of CVKD

Pham Quang X (CEO and Chairman) sold 8,285 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $4.37 ($4.26–$4.42) across 3 trades over 2026-06-03 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pham Quang X
Published Jun 5, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CVKD
Bearish
medium confidence
Mentioned
$CVKD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CVKDBearishLow
01

Why it matters

The disclosed sale adds a new data point on insider sentiment for CVKD.

02

Market read

A small insider sell by the CEO may cause modest short‑term price pressure but is unlikely to move the broader market.

03

What to watch

The CEO retains a large stake (173,224 shares) and the sale size is tiny relative to float.

Relevance 2/10Novelty 2/10Timing: filing date 2026‑06‑05

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CVKDBearishMedium confidence
Context

CEO Pham Quang X sold 8,285 shares for $36,209 via a 10b5‑1 plan, reducing his stake to 173,224 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A $36K sale by the CEO is small relative to market cap, but insider sells often trigger short‑term selling pressure.

Market effects

Sector

Minimal impact on the biotech sector; the sale is company‑specific.

Regional

No regional effect; limited to CVKD shareholders.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan and not reflect negative fundamentals.

Key entities

  • company
    Cadrenal Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker CVKD.

  • person
    Pham Quang X

    CEO and Chairman of Cadrenal Therapeutics, 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CVKD insider trading history →

Related articles

AUG 13
$CVKDMed

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the…

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio org

SEC EDGAR 8-K6 min
JUL 13
$CVKDMedAI 8/10

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.

manilatimes.net4 min
JUN 22
$CVKDMed

Cadrenal Advances Tecarfarin Toward FDA Rare Pediatric Disease Filing In Kawasaki Disease

Cadrenal Therapeutics said it plans to file for FDA Rare Pediatric Disease designation for tecarfarin in children with Kawasaki disease who develop coronary artery aneurysms. The company says tecarfarin is designed to provide more stable anticoagulation than warfarin. If approved, Cadrenal could receive a Priority Review Voucher, which it notes has sold for $180M–$205M.

rttnews.com5 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min